# A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

> **NCT01085656** · PHASE1 · TERMINATED · sponsor: **University of Florida** · enrollment: 18 (actual)

## Conditions studied

- Leukemia, Myelogenous, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** OXi4503

## Key facts

- **NCT ID:** NCT01085656
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085656, "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01085656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*